Oral β-lactam pairs for the treatment of Mycobacterium avium complex pulmonary disease.
Oral β-lactam pairs for the treatment of Mycobacterium avium complex pulmonary disease.
复制标题
口服β-内酰胺对用于治疗鸟分枝杆菌复合型肺部疾病。
DOI：
10.1093/infdis/jiad591
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Dick,Thomas
中科院分区：
文献类型：
--
作者：
Negatu,DerejeA;Shin,SungJae;Kim,Su-Young;Jhun,ByungWoo;Dartois,Véronique;Dick,Thomas
由禽分枝杆菌复合体(MAC)引起的肺部疾病的治愈率很低。虽然β-内酰胺是治疗脓肿分枝杆菌肺部疾病的一线抗生素，但它们尚未被用于或推荐用于治疗MAC肺部感染。通过对口服β-内酰胺类药物的全面筛选，我们发现，选定的青霉烯类/碳青霉烯类或青霉素与头孢菌素联合使用的药物对在临床上达到的浓度有很强的杀菌作用。这些双重β-内酰胺类药物包括泰比培南和舒罗培南，两种药物都处于第三阶段，以及食品和药物管理局批准的阿莫西林和头孢呋辛。因此，他们可以立即进入临床试验或临床实践。
Cure rates for pulmonary disease caused by theMycobacterium aviumcomplex (MAC) are poor. While β-lactam are front line antibiotics againstMycobacterium abscessuspulmonary disease, they have not been used or recommended to treat MAC lung infections. Through a comprehensive screen of oral β-lactams, we have discovered that selected pairs combining either a penem/carbapenem or penicillin with a cephalosporin are strongly bactericidal at clinically achieved concentrations. These dual β-lactam combinations include tebipenem and sulopenem, both in phase 3, and Food and Drug Administration-approved amoxicillin and cefuroxime. They could therefore immediately enter clinical trials or clinical practice.